{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:16:08Z","timestamp":1790612168168,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"deutsche forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO2155\/6-1"],"award-info":[{"award-number":["KO2155\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"deutsche forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BR1782\/5-1"],"award-info":[{"award-number":["BR1782\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"deutsche forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO2155\/7-1"],"award-info":[{"award-number":["KO2155\/7-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"deutsche forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GE2811\/4-1"],"award-info":[{"award-number":["GE2811\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"interdisziplin\u00e4res zentrum f\u00fcr klinische forschung, universit\u00e4tsklinikum w\u00fcrzburg","doi-asserted-by":"publisher","award":["grant O1-6"],"award-info":[{"award-number":["grant O1-6"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"interdisziplin\u00e4res zentrum f\u00fcr klinische forschung, universit\u00e4tsklinikum w\u00fcrzburg","doi-asserted-by":"publisher","award":["grant O1-6"],"award-info":[{"award-number":["grant O1-6"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"ministerstvo zdravotnictv\u00ed cesk\u00e9 republiky","doi-asserted-by":"publisher","award":["00023736"],"award-info":[{"award-number":["00023736"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"ministerstvo zdravotnictv\u00ed cesk\u00e9 republiky","doi-asserted-by":"publisher","award":["65269705"],"award-info":[{"award-number":["65269705"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myeloproliferative neoplasms (MPN), comprising essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are hematological disorders of the myeloid lineage characterized by hyperproliferation of mature blood cells. The prediction of the clinical course and progression remains difficult and new therapeutic modalities are required. We conducted a CD34<jats:sup>+<\/jats:sup> gene expression study to identify signatures and potential biomarkers in the different MPN subtypes with the aim to improve treatment and prevent the transformation from the rather benign chronic state to a more malignant aggressive state. We report here on a systematic gene expression analysis (GEA) of CD34<jats:sup>+<\/jats:sup> peripheral blood or bone marrow cells derived from 30 patients with MPN including all subtypes (ET (<jats:italic>n<\/jats:italic>\u2009=\u20096), PV (<jats:italic>n<\/jats:italic>\u2009=\u200911), PMF (<jats:italic>n<\/jats:italic>\u2009=\u20099), secondary MF (SMF; post-ET-\/post-PV-MF; <jats:italic>n<\/jats:italic>\u2009=\u20094)) and six healthy donors. GEA revealed a variety of differentially regulated genes in the different MPN subtypes vs. controls, with a higher number in PMF\/SMF (200\/272 genes) than in ET\/PV (132\/121). PROGEN\u03b3 analysis revealed significant induction of TNF\u03b1\/NF-\u03baB signaling (particularly in SMF) and reduction of estrogen signaling (PMF and SMF). Consistently, inflammatory GO terms were enriched in PMF\/SMF, whereas RNA splicing\u2013associated biological processes were downregulated in PMF. Differentially regulated genes that might be utilized as diagnostic\/prognostic markers were identified, such as <jats:italic>AREG<\/jats:italic>, <jats:italic>CYBB<\/jats:italic>, <jats:italic>DNTT<\/jats:italic>, <jats:italic>TIMD4<\/jats:italic>, <jats:italic>VCAM1<\/jats:italic>, and S100 family members (<jats:italic>S100A4\/8\/9\/10\/12<\/jats:italic>). Additionally, 98 genes (including <jats:italic>CLEC1B<\/jats:italic>, <jats:italic>CMTM5<\/jats:italic>, <jats:italic>CXCL8<\/jats:italic>, <jats:italic>DACH1<\/jats:italic>, and <jats:italic>RADX<\/jats:italic>) were deregulated solely in SMF and may be used to predict progression from early to late stage MPN.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s00277-021-04615-8","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T07:02:51Z","timestamp":1628924571000},"page":"2943-2956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells"],"prefix":"10.1007","volume":"100","author":[{"given":"Julian","family":"Baumeister","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Mai\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chatain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Weinbergerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo A. S.","family":"de Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Eschweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"Kubesova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"Racil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schuppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Gezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"issue":"25","key":"4615_CR1","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant\u2019Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R, (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379\u20132390. https:\/\/doi.org\/10.1056\/NEJMoa1311347","journal-title":"N Engl J Med"},{"issue":"17","key":"4615_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779\u20131790. https:\/\/doi.org\/10.1056\/NEJMoa051113","journal-title":"N Engl J Med"},{"issue":"25","key":"4615_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O\u2019Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa1312542","journal-title":"N Engl J Med"},{"issue":"6","key":"4615_CR4","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24(6):1128\u20131138. https:\/\/doi.org\/10.1038\/leu.2010.69","journal-title":"Leukemia"},{"issue":"6","key":"4615_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129(6):667\u2013679. https:\/\/doi.org\/10.1182\/blood-2016-10-695940","journal-title":"Blood"},{"issue":"4","key":"4615_CR6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A (2018) MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol 36(4):310\u2013318. https:\/\/doi.org\/10.1200\/JCO.2017.76.4886","journal-title":"J Clin Oncol"},{"issue":"15","key":"4615_CR7","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O\u2019Neil L, O\u2019Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ (2018) Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med 379(15):1416\u20131430. https:\/\/doi.org\/10.1056\/NEJMoa1716614","journal-title":"N Engl J Med"},{"issue":"11","key":"4615_CR8","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.3324\/haematol.2019.229039","volume":"104","author":"HC Hasselbalch","year":"2019","unstructured":"Hasselbalch HC (2019) Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera? Haematologica 104(11):2119\u20132125. https:\/\/doi.org\/10.3324\/haematol.2019.229039","journal-title":"Haematologica"},{"issue":"2","key":"4615_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/leu.2010.269","volume":"25","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A (2011) JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 25(2):218\u2013225. https:\/\/doi.org\/10.1038\/leu.2010.269","journal-title":"Leukemia"},{"issue":"6","key":"4615_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1182\/blood-2016-10-695965","volume":"129","author":"AM Vannucchi","year":"2017","unstructured":"Vannucchi AM, Harrison CN (2017) Emerging treatments for classical myeloproliferative neoplasms. Blood 129(6):693\u2013703. https:\/\/doi.org\/10.1182\/blood-2016-10-695965","journal-title":"Blood"},{"key":"4615_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/hematology.2020000129","volume":"1","author":"AA Patel","year":"2020","unstructured":"Patel AA (2020) Odenike O (2020) Genomics of MPN progression. Hematology Am Soc Hematol Educ Program 1:440\u2013449. https:\/\/doi.org\/10.1182\/hematology.2020000129","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"17","key":"4615_CR12","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-10-1092","volume":"16","author":"W Berkofsky-Fessler","year":"2010","unstructured":"Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S, Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD (2010) Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res 16(17):4339\u20134352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1092","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4615_CR13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2008.357","volume":"23","author":"L Catani","year":"2009","unstructured":"Catani L, Zini R, Sollazzo D, Ottaviani E, Vannucchi AM, Ferrari S, Baccarani M, Vianelli N, Lemoli RM, Manfredini R (2009) Molecular profile of CD34+ stem\/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia 23(5):997\u20131000. https:\/\/doi.org\/10.1038\/leu.2008.357","journal-title":"Leukemia"},{"issue":"1","key":"4615_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1634\/stemcells.2006-0351","volume":"25","author":"P Guglielmelli","year":"2007","unstructured":"Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazzi A, Bianchi E, Mannelli F, Ferrari S, Le Bousse-Kerdiles MC, Bosi A, Barosi G, Migliaccio AR, Manfredini R, Vannucchi AM (2007) Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms\u2019 tumor gene 1 (WT1). Stem Cells 25(1):165\u2013173. https:\/\/doi.org\/10.1634\/stemcells.2006-0351","journal-title":"Stem Cells"},{"issue":"8","key":"4615_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0135463","volume":"10","author":"VP \u010coki\u0107","year":"2015","unstructured":"\u010coki\u0107 VP, Mossuz P, Han J, Socoro N, Beleslin-\u010coki\u0107 BB, Mitrovi\u0107 O, Suboti\u010dki T, Dikli\u0107 M, Lekovi\u0107 D, Goti\u010d M, Puri RK, Noguchi CT, Schechter AN (2015) Microarray and proteomic analyses of myeloproliferative neoplasms with a highlight on the mTOR signaling pathway. PLoS ONE 10(8):1\u201323. https:\/\/doi.org\/10.1371\/journal.pone.0135463","journal-title":"PLoS ONE"},{"key":"4615_CR16","doi-asserted-by":"publisher","unstructured":"Psaila B, Wang G, Rodriguez-Meira A, Li R, Heuston EF, Murphy L, Yee D, Hitchcock IS, Sousos N, O\u2019Sullivan J, Anderson S, Senis YA, Weinberg OK, Calicchio ML, Center NIHIS, Iskander D, Royston D, Milojkovic D, Roberts I, Bodine DM, Thongjuea S, Mead AJ (2020) Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets. Mol Cell 78 (3):477\u2013492 e478. doi:https:\/\/doi.org\/10.1016\/j.molcel.2020.04.008","DOI":"10.1016\/j.molcel.2020.04.008"},{"issue":"7765","key":"4615_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","volume":"571","author":"AS Nam","year":"2019","unstructured":"Nam AS, Kim KT, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND, Alonso A, Sheridan C, Mariani M, Dai X, Harrington E, Pastore A, Cubillos-Ruiz JR, Tam W, Hoffman R, Rabadan R, Scandura JM, Abdel-Wahab O, Smibert P, Landau DA (2019) Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature 571(7765):355\u2013360. https:\/\/doi.org\/10.1038\/s41586-019-1367-0","journal-title":"Nature"},{"issue":"8","key":"4615_CR18","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1038\/s41375-018-0125-x","volume":"32","author":"M Kirschner","year":"2018","unstructured":"Kirschner M, Maurer A, Wlodarski MW, Ventura Ferreira MS, Bouillon AS, Halfmeyer I, Blau W, Kreuter M, Rosewich M, Corbacioglu S, Beck J, Schwarz M, Bittenbring J, Radsak MP, Wilk CM, Koschmieder S, Begemann M, Kurth I, Schemionek M, Brummendorf TH, Beier F (2018) Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. Leukemia 32(8):1762\u20131767. https:\/\/doi.org\/10.1038\/s41375-018-0125-x","journal-title":"Leukemia"},{"issue":"4","key":"4615_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41375-018-0295-6","volume":"33","author":"J Czech","year":"2019","unstructured":"Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maie T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brummendorf TH, Muller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sorensen AL, Holmstrom M, Kjaer L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S (2019) JAK2V617F but not CALR mutations confer increased molecular responses to interferon-alpha via JAK1\/STAT1 activation. Leukemia 33(4):995\u20131010. https:\/\/doi.org\/10.1038\/s41375-018-0295-6","journal-title":"Leukemia"},{"issue":"1","key":"4615_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8(1):118\u2013127. https:\/\/doi.org\/10.1093\/biostatistics\/kxj037","journal-title":"Biostatistics"},{"key":"4615_CR21","doi-asserted-by":"publisher","unstructured":"Nangalia J, Green AR (2017) Myeloproliferative neoplasms: from origins to outcomes. Blood 130 (23):blood-2017\u20132006\u2013782037. doi:https:\/\/doi.org\/10.1182\/blood-2017-06-782037","DOI":"10.1182\/blood-2017-06-782037"},{"issue":"1","key":"4615_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","volume":"9","author":"M Schubert","year":"2018","unstructured":"Schubert M, Klinger B, Klunemann M, Sieber A, Uhlitz F, Sauer S, Garnett MJ, Bluthgen N, Saez-Rodriguez J (2018) Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat Commun 9(1):20. https:\/\/doi.org\/10.1038\/s41467-017-02391-6","journal-title":"Nat Commun"},{"key":"4615_CR23","doi-asserted-by":"publisher","unstructured":"Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL (2018) Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell 33 (1):29\u201343 e27. doi:https:\/\/doi.org\/10.1016\/j.ccell.2017.11.009","DOI":"10.1016\/j.ccell.2017.11.009"},{"key":"4615_CR24","doi-asserted-by":"publisher","unstructured":"Hautin M, Mornet C, Chauveau A, Bernard D, Corcos L, Lippert E (2020) Splicing anomalies in myeloproliferative neoplasms: paving the way for new therapeutic venues. Cancers (Basel) 12 (8). doi:https:\/\/doi.org\/10.3390\/cancers12082216","DOI":"10.3390\/cancers12082216"},{"key":"4615_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","volume":"53","author":"Q Ma","year":"2013","unstructured":"Ma Q (2013) Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53:401\u2013426. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011112-140320","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4615_CR26","doi-asserted-by":"publisher","unstructured":"Chatain N, Koschmieder S, Jost E (2020) Role of inflammatory factors during disease pathogenesis and stem cell transplantation in myeloproliferative neoplasms. Cancers (Basel) 12 (8). doi:https:\/\/doi.org\/10.3390\/cancers12082250","DOI":"10.3390\/cancers12082250"},{"key":"4615_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.semcdb.2014.01.005","volume":"28","author":"C Berasain","year":"2014","unstructured":"Berasain C, Avila MA (2014) Amphiregulin. Semin Cell Dev Biol 28:31\u201341. https:\/\/doi.org\/10.1016\/j.semcdb.2014.01.005","journal-title":"Semin Cell Dev Biol"},{"issue":"5","key":"4615_CR28","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.cell.2015.08.021","volume":"162","author":"N Arpaia","year":"2015","unstructured":"Arpaia N, Green JA, Moltedo B, Arvey A, Hemmers S, Yuan S, Treuting PM, Rudensky AY (2015) A distinct function of regulatory T cells in tissue protection. Cell 162(5):1078\u20131089. https:\/\/doi.org\/10.1016\/j.cell.2015.08.021","journal-title":"Cell"},{"issue":"4","key":"4615_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1179\/102453310X12647083620769","volume":"15","author":"H Haouas","year":"2010","unstructured":"Haouas H, Haouas S, Uzan G, Hafsia A (2010) Identification of new markers discriminating between myeloid and lymphoid acute leukemia. Hematology 15(4):193\u2013203. https:\/\/doi.org\/10.1179\/102453310X12647083620769","journal-title":"Hematology"},{"issue":"3\u20134","key":"4615_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3109\/10428190009089432","volume":"37","author":"YO Huh","year":"2000","unstructured":"Huh YO, Smith TL, Collins P, Bueso-Ramos C, Albitar M, Kantarjian HM, Pierce SA, Freireich EJ (2000) Terminal deoxynucleotidyl transferase expression in acute myelogenous leukemia and myelodysplasia as determined by flow cytometry. Leuk Lymphoma 37(3\u20134):319\u2013331. https:\/\/doi.org\/10.3109\/10428190009089432","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"4615_CR31","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1182\/blood-2018-99-118880","volume":"132","author":"AS Paiva","year":"2018","unstructured":"Paiva AS, Paiva HDDO, Cavalcanti GB Jr, Bahia F, Freitas RV, Silveira LS Jr, Silva LK, Vasconcelos RC, Silva DG, Vl S, Gil EA, Januario G, Fernandes M, Jardim AS (2018) Importance of detection of intracellular myeloperoxidase, CD13, CD79a, CD22, CD3 and terminal deoxynucleotidyl transferase by flow cytometry diagnosis of acute leukemias. Blood 132(Supplement 1):5194\u20135194. https:\/\/doi.org\/10.1182\/blood-2018-99-118880","journal-title":"Blood"},{"issue":"4","key":"4615_CR32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00726-010-0528-0","volume":"41","author":"J Goyette","year":"2011","unstructured":"Goyette J, Geczy CL (2011) Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids 41(4):821\u2013842. https:\/\/doi.org\/10.1007\/s00726-010-0528-0","journal-title":"Amino Acids"},{"issue":"5","key":"4615_CR33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s13402-018-0392-6","volume":"41","author":"M Kovacic","year":"2018","unstructured":"Kovacic M, Mitrovic-Ajtic O, Beleslin-Cokic B, Djikic D, Suboticki T, Diklic M, Lekovic D, Gotic M, Mossuz P, Cokic VP (2018) TLR4 and RAGE conversely mediate pro-inflammatory S100A8\/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms. Cell Oncol (Dordr) 41(5):541\u2013553. https:\/\/doi.org\/10.1007\/s13402-018-0392-6","journal-title":"Cell Oncol (Dordr)"},{"issue":"10","key":"4615_CR34","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1093\/carcin\/bgn188","volume":"29","author":"O Turovskaya","year":"2008","unstructured":"Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, Nguyen M, Olsson A, Nawroth PP, Bierhaus A, Varki N, Kronenberg M, Freeze HH, Srikrishna G (2008) RAGE, carboxylated glycans and S100A8\/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29(10):2035\u20132043. https:\/\/doi.org\/10.1093\/carcin\/bgn188","journal-title":"Carcinogenesis"},{"key":"4615_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2020.11.004","author":"NB Leimkuhler","year":"2020","unstructured":"Leimkuhler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, Kuppe C, Stalmann USA, Busche G, Kreipe H, Gutgemann I, Krebs P, Banz Y, Boor P, Tai EW, Brummendorf TH, Koschmieder S, Crysandt M, Bindels E, Kramann R, Costa IG, Schneider RK (2020) Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. https:\/\/doi.org\/10.1016\/j.stem.2020.11.004","journal-title":"Cell Stem Cell"},{"issue":"18","key":"4615_CR36","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood.2019004095","volume":"136","author":"HFE Gleitz","year":"2020","unstructured":"Gleitz HFE, Dugourd AJF, Leimkuhler NB, Snoeren IAM, Fuchs SNR, Menzel S, Ziegler S, Kroger N, Triviai I, Busche G, Kreipe H, Banjanin B, Pritchard JE, Hoogenboezem R, Bindels EM, Schumacher N, Rose-John S, Elf S, Saez-Rodriguez J, Kramann R, Schneider RK (2020) Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood 136(18):2051\u20132064. https:\/\/doi.org\/10.1182\/blood.2019004095","journal-title":"Blood"},{"issue":"10","key":"4615_CR37","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A (2011) Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 29(10):1356\u20131363. https:\/\/doi.org\/10.1200\/JCO.2010.32.9490","journal-title":"J Clin Oncol"},{"issue":"2","key":"4615_CR38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/1521-4141(200002)30:2<697::AID-IMMU697>3.0.CO;2-M","volume":"30","author":"M Colonna","year":"2000","unstructured":"Colonna M, Samaridis J, Angman L (2000) Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells. Eur J Immunol 30(2):697\u2013704. https:\/\/doi.org\/10.1002\/1521-4141(200002)30:2%3c697::AID-IMMU697%3e3.0.CO;2-M","journal-title":"Eur J Immunol"},{"issue":"2","key":"4615_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1084\/jem.20050248","volume":"202","author":"M Moriyama","year":"2005","unstructured":"Moriyama M, Sato T, Inoue H, Fukuyama S, Teranishi H, Kangawa K, Kano T, Yoshimura A, Kojima M (2005) The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med 202(2):217\u2013224. https:\/\/doi.org\/10.1084\/jem.20050248","journal-title":"J Exp Med"},{"issue":"4","key":"4615_CR40","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/leu.2015.329","volume":"30","author":"M Schemionek","year":"2016","unstructured":"Schemionek M, Herrmann O, Reher MM, Chatain N, Schubert C, Costa IG, Hanzelmann S, Gusmao EG, Kintsler S, Braunschweig T, Hamilton A, Helgason GV, Copland M, Schwab A, Muller-Tidow C, Li S, Holyoake TL, Brummendorf TH, Koschmieder S (2016) Mtss1 is a critical epigenetically regulated tumor suppressor in CML. Leukemia 30(4):823\u2013832. https:\/\/doi.org\/10.1038\/leu.2015.329","journal-title":"Leukemia"},{"issue":"5","key":"4615_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125783","volume":"10","author":"M Schemionek","year":"2015","unstructured":"Schemionek M, Kharabi Masouleh B, Klaile Y, Krug U, Hebestreit K, Schubert C, Dugas M, Buchner T, Wormann B, Hiddemann W, Berdel WE, Brummendorf TH, Muller-Tidow C, Koschmieder S (2015) Identification of the adapter molecule MTSS1 as a potential oncogene-specific tumor suppressor in acute myeloid leukemia. PLoS ONE 10(5):e0125783. https:\/\/doi.org\/10.1371\/journal.pone.0125783","journal-title":"PLoS ONE"},{"issue":"19","key":"4615_CR42","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.1158\/1078-0432.CCR-06-3082","volume":"13","author":"L Shao","year":"2007","unstructured":"Shao L, Cui Y, Li H, Liu Y, Zhao H, Wang Y, Zhang Y, Ng KM, Han W, Ma D, Tao Q (2007) CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res 13(19):5756\u20135762. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3082","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4615_CR43","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s11605-011-1546-2","volume":"15","author":"D Wang","year":"2011","unstructured":"Wang D, Xu MR, Wang T, Li T, Zhu J (2011) MTSS1 overexpression correlates with poor prognosis in colorectal cancer. J Gastrointest Surg 15(7):1205\u20131212. https:\/\/doi.org\/10.1007\/s11605-011-1546-2","journal-title":"J Gastrointest Surg"},{"key":"4615_CR44","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1038\/ncomms4465","volume":"5","author":"KD Mertz","year":"2014","unstructured":"Mertz KD, Pathria G, Wagner C, Saarikangas J, Sboner A, Romanov J, Gschaider M, Lenz F, Neumann F, Schreiner W, Nemethova M, Glassmann A, Lappalainen P, Stingl G, Small JV, Fink D, Chin L, Wagner SN (2014) MTSS1 is a metastasis driver in a subset of human melanomas. Nat Commun 5:3465. https:\/\/doi.org\/10.1038\/ncomms4465","journal-title":"Nat Commun"},{"key":"4615_CR45","doi-asserted-by":"publisher","unstructured":"Dungrawala H, Bhat KP, Le Meur R, Chazin WJ, Ding X, Sharan SK, Wessel SR, Sathe AA, Zhao R, Cortez D (2017) RADX promotes genome stability and modulates chemosensitivity by regulating RAD51 at replication forks. Mol Cell 67 (3):374\u2013386 e375. doi:https:\/\/doi.org\/10.1016\/j.molcel.2017.06.023","DOI":"10.1016\/j.molcel.2017.06.023"},{"issue":"11","key":"4615_CR46","doi-asserted-by":"publisher","first-page":"8621","DOI":"10.18632\/oncotarget.3281","volume":"6","author":"Y Liu","year":"2015","unstructured":"Liu Y, Zhou R, Yuan X, Han N, Zhou S, Xu H, Guo M, Yu S, Zhang C, Yin T, Wu K (2015) DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt\/beta-catenin signaling. Oncotarget 6(11):8621\u20138634. https:\/\/doi.org\/10.18632\/oncotarget.3281","journal-title":"Oncotarget"},{"issue":"1","key":"4615_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jcp.28975","volume":"235","author":"S Chen","year":"2020","unstructured":"Chen S, Li J, Zhou P, Zhi X (2020) SPTBN1 and cancer, which links? J Cell Physiol 235(1):17\u201325. https:\/\/doi.org\/10.1002\/jcp.28975","journal-title":"J Cell Physiol"},{"key":"4615_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0926-6","author":"G Barosi","year":"2020","unstructured":"Barosi G, Rosti V, Catarsi P, Villani L, Abba C, Carolei A, Magrini U, Gale RP, Massa M, Campanelli R (2020) Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia. https:\/\/doi.org\/10.1038\/s41375-020-0926-6","journal-title":"Leukemia"},{"issue":"20","key":"4615_CR49","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.2217\/fon.15.200","volume":"11","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Komrokji RS (2015) A comprehensive review of pacritinib in myelofibrosis. Future Oncol 11(20):2819\u20132830. https:\/\/doi.org\/10.2217\/fon.15.200","journal-title":"Future Oncol"},{"key":"4615_CR50","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/102476","volume":"2015","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Bjorn ME (2015) MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm 2015:102476. https:\/\/doi.org\/10.1155\/2015\/102476","journal-title":"Mediators Inflamm"},{"issue":"9","key":"4615_CR51","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/leu.2016.377","volume":"31","author":"DAC Fisher","year":"2017","unstructured":"Fisher DAC, Malkova O, Engle EK, Miner CA, Fulbright MC, Behbehani GK, Collins TB, Bandyopadhyay S, Zhou A, Nolan GP, Oh ST (2017) Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia 31(9):1962\u20131974. https:\/\/doi.org\/10.1038\/leu.2016.377","journal-title":"Leukemia"},{"issue":"4","key":"4615_CR52","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ccell.2018.03.024","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL (2018) Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell 33(4):785\u2013787. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.024","journal-title":"Cancer Cell"},{"issue":"6","key":"4615_CR53","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.stem.2014.11.002","volume":"15","author":"A Sanchez-Aguilera","year":"2014","unstructured":"Sanchez-Aguilera A, Arranz L, Martin-Perez D, Garcia-Garcia A, Stavropoulou V, Kubovcakova L, Isern J, Martin-Salamanca S, Langa X, Skoda RC, Schwaller J, Mendez-Ferrer S (2014) Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell 15(6):791\u2013804. https:\/\/doi.org\/10.1016\/j.stem.2014.11.002","journal-title":"Cell Stem Cell"},{"issue":"Supplement 1","key":"4615_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2020-134764","volume":"136","author":"C Harrison","year":"2020","unstructured":"Harrison C, Baxter J, Boucher RH, McKerrell T, Jackson A, Fletcher RS, Mead AJ, Knapper S, Ewing J, Butt NM, Jain M, Francis S, Clark FJ, Coppell J, McMullin MF, Wadelin F, Narayanan S, Milojkovic D, Drummond MW, Sekhar M, Paramor M, Roberts J, Glover R, Harris E, Grassi L, Rodriguez-Meira A, Carroll J, Mart\u00edn J-E, Corbizi Fattori G, Fang Z, Godfrey AL, M\u00e9ndez-Ferrer S (2020) Effects of tamoxifen on the mutant allele burden and disease course in patients with myeloproliferative neoplasms - results of the Tamarin Study. Blood 136(Supplement 1):33\u201335. https:\/\/doi.org\/10.1182\/blood-2020-134764","journal-title":"Blood"},{"issue":"5","key":"4615_CR55","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/leu.2016.12","volume":"30","author":"S Koschmieder","year":"2016","unstructured":"Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Maria Vannucchi A, Cervantes F, Silver RT, Barbui T (2016) Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia 30(5):1018\u20131024. https:\/\/doi.org\/10.1038\/leu.2016.12","journal-title":"Leukemia"},{"key":"4615_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100711","volume":"42","author":"S Koschmieder","year":"2020","unstructured":"Koschmieder S, Chatain N (2020) Role of inflammation in the biology of myeloproliferative neoplasms. Blood Rev 42:100711. https:\/\/doi.org\/10.1016\/j.blre.2020.100711","journal-title":"Blood Rev"},{"issue":"26","key":"4615_CR57","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1182\/blood-2017-05-784942","volume":"130","author":"M Nieborowska-Skorska","year":"2017","unstructured":"Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T (2017) Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood 130(26):2848\u20132859. https:\/\/doi.org\/10.1182\/blood-2017-05-784942","journal-title":"Blood"},{"issue":"11","key":"4615_CR58","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/leu.2013.102","volume":"27","author":"C Marty","year":"2013","unstructured":"Marty C, Lacout C, Droin N, Le Cou\u00e9dic JP, Ribrag V, Solary E, Vainchenker W, Villeval JL, Plo I (2013) A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 27(11):2187\u20132195. https:\/\/doi.org\/10.1038\/leu.2013.102","journal-title":"Leukemia"},{"key":"4615_CR59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000162","author":"T Nageswara Rao","year":"2019","unstructured":"Nageswara Rao T, Hansen N, Hilfiker J, Rai S, Majewska JM, Lekovic D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kroger N, Hess C, Radimerski T, Koschmieder S, Cokic VP, Skoda RC (2019) JAK2 mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. https:\/\/doi.org\/10.1182\/blood.2019000162","journal-title":"Blood"},{"key":"4615_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0629-z","author":"J Baumeister","year":"2019","unstructured":"Baumeister J, Chatain N, Hubrich A, Maie T, Costa IG, Denecke B, Han L, Kustermann C, Sontag S, Sere K, Strathmann K, Zenke M, Schuppert A, Brummendorf TH, Kranc KR, Koschmieder S, Gezer D (2019) Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms. Leukemia. https:\/\/doi.org\/10.1038\/s41375-019-0629-z","journal-title":"Leukemia"},{"key":"4615_CR61","doi-asserted-by":"publisher","unstructured":"Hasselbalch HC, Thomassen M, Riley CH, Kjaer L, Larsen TS, Jensen MK, Bjerrum OW, Kruse TA, Skov V (2014) Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. PLoS One 9 (11):e112786. doi:https:\/\/doi.org\/10.1371\/journal.pone.0112786","DOI":"10.1371\/journal.pone.0112786"},{"issue":"3","key":"4615_CR62","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/ncb2699","volume":"15","author":"JJ Tsai","year":"2013","unstructured":"Tsai JJ, Dudakov JA, Takahashi K, Shieh JH, Velardi E, Holland AM, Singer NV, West ML, Smith OM, Young LF, Shono Y, Ghosh A, Hanash AM, Tran HT, Moore MA, van den Brink MR (2013) Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol 15(3):309\u2013316. https:\/\/doi.org\/10.1038\/ncb2699","journal-title":"Nat Cell Biol"},{"issue":"3","key":"4615_CR63","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1189\/jlb.1008647","volume":"86","author":"JM Ehrchen","year":"2009","unstructured":"Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J (2009) The endogenous Toll-like receptor 4 agonist S100A8\/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86(3):557\u2013566. https:\/\/doi.org\/10.1189\/jlb.1008647","journal-title":"J Leukoc Biol"},{"issue":"2","key":"4615_CR64","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1600-0609.2008.01163.x","volume":"82","author":"K Abdulkarim","year":"2009","unstructured":"Abdulkarim K, Girodon F, Johansson P, Maynadie M, Kutti J, Carli PM, Bovet E, Andreasson B (2009) AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol 82(2):106\u2013111. https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01163.x","journal-title":"Eur J Haematol"},{"issue":"10","key":"4615_CR65","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1038\/leu.2014.95","volume":"28","author":"M Braig","year":"2014","unstructured":"Braig M, Pallmann N, Preukschas M, Steinemann D, Hofmann W, Gompf A, Streichert T, Braunschweig T, Copland M, Rudolph KL, Bokemeyer C, Koschmieder S, Schuppert A, Balabanov S, Brummendorf TH (2014) A \u2018telomere-associated secretory phenotype\u2019 cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. Leukemia 28(10):2028\u20132039. https:\/\/doi.org\/10.1038\/leu.2014.95","journal-title":"Leukemia"},{"key":"4615_CR66","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fphys.2013.00133","volume":"4","author":"SL Chan","year":"2013","unstructured":"Chan SL, Baumbach GL (2013) Deficiency of Nox2 prevents angiotensin II-induced inward remodeling in cerebral arterioles. Front Physiol 4:133. https:\/\/doi.org\/10.3389\/fphys.2013.00133","journal-title":"Front Physiol"},{"issue":"12","key":"4615_CR67","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1210\/mend.11.12.0023","volume":"11","author":"SY Hsu","year":"1997","unstructured":"Hsu SY, Kaipia A, Zhu L, Hsueh AJ (1997) Interference of BAD (Bcl-xL\/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14\u20133-3 isoforms and P11. Mol Endocrinol 11(12):1858\u20131867. https:\/\/doi.org\/10.1210\/mend.11.12.0023","journal-title":"Mol Endocrinol"},{"issue":"12","key":"4615_CR68","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.neo.2018.09.007","volume":"20","author":"AK Brenner","year":"2018","unstructured":"Brenner AK, Bruserud O (2018) S100 proteins in acute myeloid leukemia. Neoplasia 20(12):1175\u20131186. https:\/\/doi.org\/10.1016\/j.neo.2018.09.007","journal-title":"Neoplasia"},{"issue":"1","key":"4615_CR69","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/s1521-6616(02)00043-8","volume":"107","author":"P Rouleau","year":"2003","unstructured":"Rouleau P, Vandal K, Ryckman C, Poubelle PE, Boivin A, Talbot M, Tessier PA (2003) The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis. Clin Immunol 107(1):46\u201354. https:\/\/doi.org\/10.1016\/s1521-6616(02)00043-8","journal-title":"Clin Immunol"},{"issue":"10","key":"4615_CR70","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1080\/21645515.2015.1056953","volume":"11","author":"L Cheng","year":"2015","unstructured":"Cheng L, Ruan Z (2015) Tim-3 and Tim-4 as the potential targets for antitumor therapy. Hum Vaccin Immunother 11(10):2458\u20132462. https:\/\/doi.org\/10.1080\/21645515.2015.1056953","journal-title":"Hum Vaccin Immunother"},{"key":"4615_CR71","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.canlet.2018.08.012","volume":"436","author":"X Tan","year":"2018","unstructured":"Tan X, Zhang Z, Yao H, Shen L (2018) Tim-4 promotes the growth of colorectal cancer by activating angiogenesis and recruiting tumor-associated macrophages via the PI3K\/AKT\/mTOR signaling pathway. Cancer Lett 436:119\u2013128. https:\/\/doi.org\/10.1016\/j.canlet.2018.08.012","journal-title":"Cancer Lett"},{"issue":"2","key":"4615_CR72","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41375-020-0880-3","volume":"35","author":"Y Ozono","year":"2021","unstructured":"Ozono Y, Shide K, Kameda T, Kamiunten A, Tahira Y, Sekine M, Akizuki K, Nakamura K, Iwakiri H, Sueta M, Hidaka T, Kubuki Y, Yamamoto S, Hasuike S, Sawaguchi A, Nagata K, Shimoda K (2021) Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice. Leukemia 35(2):454\u2013467. https:\/\/doi.org\/10.1038\/s41375-020-0880-3","journal-title":"Leukemia"},{"issue":"10","key":"4615_CR73","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1172\/JCI90312","volume":"128","author":"B Edelmann","year":"2018","unstructured":"Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC, Nimmagadda SC, Muller P, Braun-Dullaeus R, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel FH, Schraven B, Isermann B, Muller AJ, Fischer T (2018) JAK2-V617F promotes venous thrombosis through beta1\/beta2 integrin activation. J Clin Invest 128(10):4359\u20134371. https:\/\/doi.org\/10.1172\/JCI90312","journal-title":"J Clin Invest"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04615-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T07:07:28Z","timestamp":1660201648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04615-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":73,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4615"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04615-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,14]]},"assertion":[{"value":"22 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PB and BM samples from MPN patients were obtained at the Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation at Uniklinik RWTH Aachen after written informed consent and approval of the local ethics committee (EK127\/12). Unfractionated BM samples from JAK2V617F-positive untreated MPN patients within the CELL project \u2014 MPN database (MIND) \u2014 after written informed consent were provided from the Department of Internal Medicine, Hematology and Oncology of Brno University Hospital, Czech Republic. Femoral heads were obtained from the Department of Orthopedics from the Uniklinik RWTH Aachen, each after written informed consent and in compliance with the local ethics committee (EK300\/13).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"See \u201cEthics approval.\u201d","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The patients\u2019 written informed consent includes a statement that their data will be published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SK reports advisory board activity for Pfizer, Incyte\/Ariad, Novartis, AOP Pharma, BMS, CTI, Roche, Baxalta, Sanofi; honoraria from Novartis, BMS, Pfizer, Incyte\/Ariad, Shire, Roche, AOP Pharma, Janssen; research funding from Novartis Foundation, BMS, Novartis; and other financial disclosures (i.e., travel support) from Alexion, Novartis, BMS, Incyte\/Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, and Janssen. THB reports consultancy from Pfizer, Novartis, Janssen, Merck, Incyte\/Ariad and research funding from Pfizer and Novartis. DG reports advisory board activity for AMGEN, Celgene, and TAKEDA; travel grants for AMGEN, Celgene, and TAKEDA; and was invited speaker for AMGEN, Celgene, BMS, and TAKEDA. The remaining authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}